Original ResearchPublished 11 September 2026Efficacy and safety of tapinarof cream once daily in Japanese pediatric patients with atopic dermatitis: a 60-week phase 3 trial consisting of an 8-week, double-blind, vehicle-controlled period and a 52-week, open-label extension periodAtsuyuki Igarashi · Gaku Tsuji · Ryusei Murata · Shuichi Fukasawa · Satoshi YamaneJournal of Cutaneous Immunology and Allergydoi 10.3389/jcia.2026.17307
Original ResearchPublished 8 September 2026Association between severity of different body regions and inadequate control of atopic dermatitis: results from a cross-sectional and longitudinal studyZifan Li · Ruoxi Yu · Ying LinFrontiers in Allergydoi 10.3389/falgy.2026.1888094
ReviewPublished 15 April 2026Bispecific and trispecific antibodies in atopic dermatitis: a review of the emerging clinical pipelineGili Amid-Toby · Omar Alani · Christopher G. BunickFrontiers in Drug Discoverydoi 10.3389/fddsv.2026.1766021
Science archivePublished 9 July 2025Real-world safety and effectiveness of dupilumab for the treatment of atopic dermatitis: two-year post-marketing surveillance in JapanHidehisa Saeki · Makiko Usami · Katsuhisa Suzuki · Michika Mochizuki · Kazuhiko ArimaJournal of Cutaneous Immunology and Allergydoi 10.3389/jcia.2025.14794
Science archivePublished 10 June 2025An open-label interventional clinical study evaluating sweating function in dupilumab treatment for atopic dermatitisMai Matsumoto · Yuta Koike · Motoi Takenaka · Hiroyuki MurotaJournal of Cutaneous Immunology and Allergydoi 10.3389/jcia.2025.14517
